Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
48 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Bacillus Anthracis Infections - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Bacillus Anthracis Infections - Pipeline Review, H2 2014', provides an overview of the Bacillus Anthracis Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Bacillus Anthracis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacillus Anthracis Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Bacillus Anthracis Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bacillus Anthracis Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bacillus Anthracis Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bacillus Anthracis Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Bacillus Anthracis Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bacillus Anthracis Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Bacillus Anthracis Infections Overview 7 Therapeutics Development 8 Pipeline Products for Bacillus Anthracis Infections - Overview 8 Pipeline Products for Bacillus Anthracis Infections - Comparative Analysis 9 Bacillus Anthracis Infections - Therapeutics under Development by Companies 10 Bacillus Anthracis Infections - Therapeutics under Investigation by Universities/Institutes 11 Bacillus Anthracis Infections - Pipeline Products Glance 12 Early Stage Products 12 Unknown Stage Products 13 Bacillus Anthracis Infections - Products under Development by Companies 14 Bacillus Anthracis Infections - Products under Investigation by Universities/Institutes 15 Bacillus Anthracis Infections - Companies Involved in Therapeutics Development 16 Aphios Corporation 16 Cellceutix Corporation 17 ContraFect Corporation 18 Evolva SA 19 Microbiotix, Inc. 20 Bacillus Anthracis Infections - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 27 Drug Profiles 29 CF-306 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Epimerox - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 EV-009 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Marinus - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 PMX-0196 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 PMX-0231 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 PMX-0243 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 PMX-225 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 RC-100b - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecule to Inhibit DNA Helicase for Infectious Diseases - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecule to Inhibit Enoyl-Reductase for Bacillus Anthracis and Francisella Tularensis Infections - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Synthetic Peptide for Bacterial Infections - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 TAA/ecdCD40L - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Bacillus Anthracis Infections - Recent Pipeline Updates 45 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 48 Disclaimer 48
List of Tables Number of Products under Development for Bacillus Anthracis Infections, H2 2014 8 Number of Products under Development for Bacillus Anthracis Infections - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 Number of Products under Investigation by Universities/Institutes, H2 2014 11 Comparative Analysis by Early Stage Development, H2 2014 12 Comparative Analysis by Unknown Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Products under Investigation by Universities/Institutes, H2 2014 15 Bacillus Anthracis Infections - Pipeline by Aphios Corporation, H2 2014 16 Bacillus Anthracis Infections - Pipeline by Cellceutix Corporation, H2 2014 17 Bacillus Anthracis Infections - Pipeline by ContraFect Corporation, H2 2014 18 Bacillus Anthracis Infections - Pipeline by Evolva SA, H2 2014 19 Bacillus Anthracis Infections - Pipeline by Microbiotix, Inc., H2 2014 20 Assessment by Monotherapy Products, H2 2014 21 Number of Products by Stage and Target, H2 2014 23 Number of Products by Stage and Mechanism of Action, H2 2014 25 Number of Products by Stage and Route of Administration, H2 2014 26 Number of Products by Stage and Molecule Type, H2 2014 28 Bacillus Anthracis Infections Therapeutics - Recent Pipeline Updates, H2 2014 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.